Quanterix Corporation (QTRX) is a Billerica, Massachusetts-based life sciences toolmaker whose Simoa ultrasensitive protein detection platform and spatial biology instruments serve research labs, biopharma partners and, increasingly, clinical diagnostics — most visibly its LucentAD blood-based Alzheimer's tests. Shares traded at $1.825 in Thursday's session, down 11.59% from the prior close of $2.07, after touching $1.765, a new 52-week low. The direction is unambiguously lower, and the decline is a continuation of Wednesday's 27.6% plunge rather than a reversal. The immediate reason markets cite is the sudden exit of the chief executive, announced Wednesday morning, though no new company-specific disclosure has been issued Thursday.
Quanterix disclosed Wednesday that Everett Cunningham had stepped down as president, chief executive and board member effective immediately to take another role elsewhere in healthcare, roughly ten months after starting the job. The board named Chief Commercial Officer Jim Gute — himself only appointed in August 2026 — as interim president and CEO and has hired a search firm, with Cunningham remain available through December 11 to support the transition.
The market reaction reflects governance risk more than an operational shock: a company mid-way through a commercial turnaround and a diagnostics build-out now has an interim leader with limited tenure and no confirmed timeline for a permanent replacement. The board reaffirmed the 2026 outlook, which limited the damage on Wednesday but did not halt the follow-through selling on Thursday.
The leadership change landed nine days after third-quarter results that were mixed. Revenue of $35.0 million beat consensus and rose 6.3% sequentially, with spatial consumables near record levels and LucentAD test volumes roughly doubling quarter over quarter. But revenue was still down 13.1% year over year, the net loss was $21.6 million, and adjusted EBITDA remained negative at $12.2 million. Management narrowed full-year revenue guidance to $142–$146 million, with non-GAAP gross margin of 48%–50%, and projected roughly $70 million of cash at year-end after about $16.2 million of quarterly cash usage.
That combination — sequential improvement against a still-declining annual base and continued cash consumption — leaves little margin for execution error, and it amplifies the impact of a leadership surprise. An insider buying pattern and a modest $3.33 average analyst target have not been enough to arrest the slide.
Volume has been heavy: roughly 3.5 million shares traded Wednesday, about five to six times the 20-day average near 620,000, and Thursday's turnover of close to 900,000 shares by midday kept activity elevated versus normal. The stock is far below its 50-day moving average around $3.05 and its 200-day average near $3.61, and the break of the prior $2.045 low is a technically significant event that tends to invite momentum-driven selling. Short interest of about 4.56 million shares, equal to more than ten days of average volume, adds sensitivity to further weakness. The move was idiosyncratic — life science tools peers were mixed to firmer — so this is a single-name repricing, not a sector or index story.
The score runs from 0, meaning no meaningful news and a move normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Quanterix scores 42 out of 100. The verified news is substantive for a company of this size — an unplanned CEO exit with an interim replacement and no permanent successor, layered on a quarter that still showed a double-digit annual revenue decline — but guidance was reaffirmed and no fundamental asset was lost. The price move was roughly 2.7 times the stock's typical daily swing of about 4.3%, and only two of the past 60 sessions produced an equal or larger move. Strong-but-not-transformative news plus a moderately unusual move combine into a mid-range score.
Attention now turns to the permanent CEO search and whether the board promotes internally or recruits externally. Operationally, investors will watch LucentAD reimbursement momentum — Florida Medicaid coverage took effect November 1 at roughly $480 per test — new clinical reference lab partnerships, and the company's targeted 2027 submission for an in vitro diagnostic claim on its HD-X instrument. Fourth-quarter and full-year 2026 results, expected in the first quarter of 2027, will be the first test of the reaffirmed $142–$146 million revenue range and the roughly $70 million year-end cash target. Risks include continued cash consumption, competitive pressure in Alzheimer's blood testing from already-approved rivals, thin analyst coverage and the possibility of further management turnover before a permanent leader is installed.
Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but the Trending AI Robots page narrows that universe to the strategies performing strongest under current market conditions. The bots differ widely by approach, holding period, risk profile, traded symbols and performance metrics, so the curated list changes as market regimes shift. For traders who want to see which automated strategies are working right now, it is a practical starting point for further research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where QTRX declined for three days, in 299 of 340 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTRX as a result. In 76 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for QTRX turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
QTRX moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for QTRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
The RSI Indicator entered the oversold zone -- be on the watch for QTRX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +22.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTRX advanced for three days, in 209 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
QTRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 128 of 144 cases where QTRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (4.142). P/E Ratio (-1.105) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.894) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. QTRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of protein diagnostic platform
Industry MedicalNursingServices